LOXL2-Mediated Matrix Remodeling in Metastasis and Mammary Gland Involution

Holly E. Barker1, Joan Chang1, Thomas R. Cox1,2, Georgina Lang1,2, Demelza Bird1,2, Monica Nicolau3, Holly R. Evans4, Alison Gartland4, and Janine T. Erler1,2

Abstract

More than 90% of cancer patient mortality is attributed to metastasis. In this study, we investigated a role for the lysyl oxidase-related enzyme lysyl oxidase-like 2 (LOXL2) in breast cancer metastasis, in both patient samples and in vivo models. Analysis of a published microarray data set revealed that LOXL2 expression is correlated with metastasis and decreased survival in patients with aggressive breast cancer. In immunocompetent or immunocompromised orthotopic and transgenic breast cancer models we showed that genetic, chemical or antibody-mediated inhibition of LOXL2 resulted in decreased metastasis. Mechanistic investigations revealed that LOXL2 promotes invasion by regulating the expression and activity of the extracellular proteins tissue inhibitor of metalloproteinase-1 (TIMP1) and matrix metalloproteinase-9 (MMP9). We found that LOXL2, TIMP1, and MMP9 are coexpressed during mammary gland involution, suggesting they function together in glandular remodeling after weaning. Finally, we found that LOXL2 is highly expressed in the basal/myoepithelial mammary cell lineage, like many other genes that are upregulated in basal-like breast cancers. Our findings highlight the importance of LOXL2 in breast cancer progression and support the development of anti-LOXL2 therapeutics for the treatment of metastatic breast cancer. Cancer Res; 71(5): 1561–72. ©2011 AACR.

Introduction

The development of therapies to treat metastatic disease has become increasingly important due to the high mortality rate associated with metastasis (1). Understanding how tumors become invasive and metastasize to secondary sites is crucial for the identification of new targets and development of new therapies for the treatment of aggressive cancers (2).

Lysyl oxidase-like 2 (LOXL2) is a member of the LOX family of extracellular matrix (ECM)-modifying enzymes comprising of LOX and LOXL1-4, all implicated in cancer progression (3). LOXL2 catalyzes the cross-linking of collagens and elastin (4, 5). Increased LOXL2 expression is associated with poor prognosis in patients with colon, esophageal, and squamous cell cancers (6, 7), and was found to promote gastric cancer metastasis (8). LOXL2 plays a role in invasion of various tumor cells (8–10) including breast cancer cells (11), and elevated LOXL2 mRNA expression was reported in highly invasive human breast cancer cell lines (12). High LOXL2 levels are associated with tumor grade in human breast cancer samples (13), found in breast carcinoma effusions (14), and negatively associated with disease-free survival in lymph node negative breast adenocarcinomas (7). However, no previous reports have investigated the relationship between LOXL2 expression and metastasis in breast cancer patients.

In this article, we are the first to show that LOXL2 expression correlates with metastasis and poor survival in breast cancer patients. Furthermore, we show a critical role for LOXL2 in breast cancer metastasis in vivo and provide preclinical evidence that targeting LOXL2 is highly effective against spontaneous lung, liver, and bone metastases. We show that the effects of LOXL2 on invasion are mediated through regulation of tissue inhibitor of metalloproteinase-1 (TIMP1). Finally, we provide novel data suggesting a previously uncharacterized role for LOXL2 in invasion during mammary gland development, and show that LOXL2 expression is associated with basal/myoepithelial cells in the mammary gland.

Materials and Methods

Patient data analysis

We used the NKI cohort of 295 tumors (15), combined with normal tissue microarray data from Stanford Hospital (16). Of the 13 normal tissue samples, 4 were obtained from reduction mammoplasty and 9 were normal tissue from cancer patients. Expression data were first transformed using Disease-Specific Genomic Analysis (DSGA; ref. 16). We used DSGA-transformed levels of estrogen receptor 1 (ESR1) in the cohort to identify...
tumors that are estrogen receptor negative (ER−; ESR1 levels less than −3.8 were considered to be ER−; Supplementary Fig. 1). LOXL2 levels were measured in the 72 ER− tumors, and Kaplan–Meier survival curves computed to compare tumors whose LOXL2 levels were in the top 1/3 (high) versus the bottom 1/3 (low) groups.

**Generation of cell lines**

The 4T1 mouse breast cancer cells were a kind gift from Fred Miller (17). MDA-MB-231 human breast cancer cells were obtained from American Type Culture Collection. Both cell lines were authenticated using short tandem repeat (STR) analysis within the last 6 months. Cells were grown in DMEM media (Invitrogen) supplemented with 10% fetal calf serum. The 4T1 and MDA-MB-231 cells were infected with lentiviruses expressing short hairpin RNA (shRNA) libraries specific to mouse (TRC-Mm1.0) or human (TRC-Hs 1.0, Open Biosystems) LOXL2, respectively.

**Quantitative real-time PCR**

Total RNA was isolated from snap-frozen mammary glands or cell pellets using RNeasy Mini Kits (Qiagen). DNase treatment and cDNA synthesis were done using Quant iTect Reverse Transcription Kits (Qiagen). Quantitative real-time PCR (qRT-PCR) for mouse β-actin, LOXL2, K14, and human β-actin and LOXL2 was done using TaqMan Gene Expression Assays (Applied Biosystems).

**Western blotting**

Conditioned media (CM) was obtained as previously described (18). Lysates were prepared from cell pellets or mammary gland tissue in urea lysis buffer. Proteins from CM and lysates were separated on NuPAGE Novex Bis-Tris 10% gels (Invitrogen). The gels were transferred to polyvinylidene difluoride membranes (Millipore) and probed with antibodies specific to human LOXL2, TIMP1, β-actin (Abcam), mouse LOXL2 (Santa Cruz Biotechnology Inc.), or TIMP1 (R&D Systems).

**LOXL2 activity assay**

Fluorescence-based enzymatic activity assays were carried out as previously described (19), using 1 to 10 μmol/L D-penicillamine to determine LOXL2-specific activity.

**In vivo assays**

For orthotopic models, control and shLOXL2 4T1 cells (1 × 10⁵) or MDA-MB-231 cells (1 × 10⁷) were injected into the fourth mammary fat pad of 6- to 8-week-old female BALB/c (Harlan) or Nude (Charles River) mice, respectively. MMTV-PyMT (mouse mammary tumor virus-polyoma middle T antigen) mice provided a transgenic model (20). Breeding pairs of these mice were kindly provided by Don White. FVB mice were used for mammary gland development studies and number of suckling pups limited to 10 for lactation and involution time points. All experiments were approved by the Home Office and conducted following United Kingdom Coordinating Committee on Cancer Research (UKCCCR) Guidelines for the welfare and use of animals in cancer research.

Treated mice received biweekly intraperitoneal injections of D-penicillamine (Sigma) at 150 mg/kg, anti-LOXL2 antibody (Santa Cruz Biotechnology Inc.) or immunoglobulin G (IgG) from goat serum (Sigma) at 0.5 mg/kg for 4 weeks. Caliper measurements of the primary tumor size were taken 3 times a week, until a maximum size was reached at which point mice were culled. The tumors, organs, and legs were removed and either fixed in 4% paraformaldehyde or flash frozen.

Lung and liver metastases were classified as any cluster of 4 or more abnormal cells (21), and were quantified in sections stained with hematoxylin and eosin (n = 3 sections per mouse). Tibias and femora were scanned using a CT scanner (model 1172; SkyScan). Images were captured every 0.7° through 180° rotation of the bone and reconstructed using the SkyScan Recon software to create three-dimensional (3D) models of each bone using the SkyScan CT analysis software. Osteolytic lesions were assessed in the 3D models of the tibias and femora, using an automated method and ImageJ software (NIH).

**Invasion and 3D assays**

Collagen invasion, transwell invasion, and 3D growth assays were carried out as previously described (21–23). Cells were transfected with SMARTpool siRNAs specific for human LOXL2 (Dharmacon). Recombinant human TIMP1 (R&D systems) was added to wells at a final concentration of 10 nmol/L.

**Immunohistochemistry/immunofluorescence**

Staining was done as previously described (21, 24) using antibodies described above plus cytokeratin 14 (Abcam). Alexa Fluor secondary antibodies were used for immunofluorescence (Molecular Probes, Invitrogen).

**Mammary epithelial cell preparation and sorting**

Mammary epithelial cell preparation and sorting was done as previously described (25) using anti-CD4–FITC, anti-CD45–PE–Cy5, anti-Sca–1–PE BD Biosciences antibodies.

**Statistical analysis**

Data were analyzed using the Student’s t test unless otherwise stated, and considered significant when P < 0.05. All statistical tests were 2 sided. Bar graphs represent the mean and standard error across independent experimental repeats unless otherwise stated. Statistical significance representations: *P < 0.05, **P < 0.01, and ***P < 0.001.

**Results**

**LOXL2 correlates with metastasis and survival**

We first carried out a retrospective study to assess whether LOXL2 mRNA expression levels correlate with metastasis and survival of breast cancer patients, employing a previously published data set (15). We found that patients with ER− tumors expressing high levels of LOXL2 have a significantly poorer prognosis. Moreover, LOXL2 expression significantly correlated with decreased overall survival and metastasis-free survival (P = 0.023 and P = 0.0367, respectively; Fig. 1A and B).
LOXL2 is not required for primary tumor growth

To investigate the role of LOXL2 in breast cancer metastasis, we chose 2 ER– breast cancer cell lines for our studies: human MDA-MB-231 and mouse 4T1 cells. Both cell lines expressed high levels of secreted LOXL2 protein, 2 forms detected in mouse (150 + 60 kDa) and 1 in human (120 kDa; Supplementary Fig. 2B). Three lines of 4T1 mouse breast cancer cells stably expressing either a shRNA specific to mouse LOXL2 (4T1shLOXL2#1 and 4T1shLOXL2#2), or a scrambled control sequence (4T1control) were generated. In addition, 2 lines of MDA-MB-231 human breast cancer cells stably expressing either a shRNA specific to human LOXL2 (MDA-MB-231shLOXL2) were generated. All the shLOXL2 cell lines had significantly decreased expression of LOXL2 mRNA and protein compared with controls (Supplementary Fig. 2A and B). Knockdown of LOXL2 in MDA-MB-231 was also achieved using siRNA (Supplementary Fig. 2B). Importantly, LOXL2 knockdown reduced LOXL2 enzymatic activity (Supplementary Fig. 2C). D-penicillamine, a chemical inhibitor of LOXL2, was also used to inhibit LOXL2 activity (Supplementary Fig. 2C; ref. 26).

The expression levels of LOXL1, LOXL3, and LOXL4 were unchanged in shLOXL2 cell lines (data not shown). In contrast, LOX expression seemed to be increased in 4T1shLOXL2 cells (Supplementary Fig. 2D), but not in the MDA-MB-231shLOXL2 cells (data not shown). It was noted that knockdown of LOXL2 had no effect on the proliferation of 4T1 or MDA-MB-231 cells in two-dimensional cultures (Supplementary Fig. 3A).

To assess the role of LOXL2 in primary tumor formation, control and shLOXL2 cells were implanted into the mammary fat pad of mice (orthotopic site). The 4T1s cells were injected into immunocompetent syngeneic BALB/c mice, and MDA-MB-231s were injected into immunocompromised nude mice. Half of the mice injected with 4T1 control cells received biweekly doses of D-penicillamine, a chemical inhibitor of LOXL2 activity (26). Mice injected with 4T1shLOXL2 cells developed mammary tumors at a faster rate than mice injected with control cells; however, no difference was observed in primary tumor growth between MDA-MB-231 control and shLOXL2 tumors (Supplementary Fig. 3B). Consistent with this, treatment with D-penicillamine had no effect on 4T1 tumor growth rate (Supplementary Fig. 3B). Thus, LOXL2 is not required for primary tumor growth.

LOXL2 enables metastases in vivo

Full necropsies of the mice were done at time of sacrifice, when tumors reached maximum permitted size. Strikingly, mice bearing 4T1shLOXL2 tumors or control tumors treated with D-penicillamine developed significantly fewer lung metastases than untreated mice bearing control tumors ($P = 0.044$, $P = 0.013$, and $P = 0.017$ for D-penicillamine–treated shLOXL2#1 and shLOXL2#2 tumors, respectively; Fig. 2A). Mice bearing MDA-MB-231shLOXL2 tumors also developed significantly fewer lung metastases than mice bearing control tumors ($P = 0.002$; Supplementary Fig. 3C). As 4T1 tumors readily metastasize to liver and bone, we also quantified metastases to these organs. Consistent with the lung data, mice bearing shLOXL2 tumors or control tumors treated with D-penicillamine developed significantly fewer liver metastases than untreated mice bearing control tumors ($P = 0.032$, $P = 0.009$, and $P = 0.010$ for D-penicillamine–treated, shLOXL2#1 and shLOXL2#2 tumors, respectively; Fig. 2B). In addition, smaller lung and liver metastases were observed in response to LOXL2 inhibition (Fig. 2A and B). These mice also developed significantly fewer bone lesions ($P = 0.023$ for shLOXL2#2 tibias, and $P = 0.015$ and $P = 0.007$ for shLOXL2#1 and shLOXL2#2 femora, respectively; Fig. 2C). Mice bearing shLOXL2#2 tumors also displayed significantly smaller lesions ($P = 0.047$ and $P = 0.036$ for tibias and femora, respectively; Supplementary Fig. 3D). These results suggest that LOXL2 is needed for metastatic colonization and metastatic growth.

Proliferation was found to be unchanged in tumors of mice bearing control and shLOXL2 tumors (Supplementary Fig. 4A). In contrast, apoptosis was increased in shLOXL2...
Figure 2. LOXL2 enables metastases in vivo. A, quantification of lung metastases formed after orthotopic injection of 4T1 control (cont; wild-type, or expressing a scrambled control shRNA) and shLOXL2 cells. Mice were either untreated or treated with D-penicillamine (D-pen). At least n = 9 mice per group. Representative images are shown in right. Scale bar, 200 μm. B, quantification of liver metastases in mice bearing 4T1 control or shLOXL2 orthotopic tumors. Representative images are shown in right. Scale bar, 200 μm. C, quantification of bone metastases in mice bearing 4T1 control or shLOXL2 orthotopic tumors. Representative CT images are shown in right. D, left: Quantification of lung metastases formed after orthotopic injection of 4T1 cells. Mice were treated with IgG or LOXL2-specific antibody. n = 5 mice per group. ** denotes P < 0.005. Right: Quantification of lung metastases formed in MMTV-PyMT transgenic mice. Mice were either untreated or treated with D-pen. n = 14 mice per group. * P < 0.05, ** P < 0.01.
tumors compared with control tumors (Supplementary Fig. 4B). However, these changes did not affect primary tumor growth (Supplementary Fig. 3B). Furthermore, no changes in proliferation or apoptosis were observed in metastatic lung tumors (data not shown). These findings suggest that LOXL2 enhances metastatic colonization and growth but does not affect proliferation or apoptosis in lesions formed.

Tumors were stained with antibodies specific for all LOX family members. Consistent with our in vitro findings, LOXL2 expression was reduced in shLOXL2 tumors (Supplementary Fig. 4C), the expression levels of LOXL1, LOXL3, or LOXL4 were unchanged (data not shown), and the expression of LOX was increased in 4T1shLOXL2 tumors (Supplementary Fig. 4C) but not in MDA-MB-231shLOXL2 tumors (data not shown).

We additionally tested a specific LOXL2-targeting antibody in the 4T1 syngeneic model of breast cancer metastasis. Mice were given biweekly injections of either a LOXL2 antibody or an isotype-matched control IgG antibody. No difference was observed in primary tumor growth rate between mice treated with the LOXL2 antibody and controls (data not shown). However, a significant decrease was observed in the number of metastases present in lungs of mice treated with LOXL2 antibody compared with controls (P = 0.005; Fig. 2D). These results show that inhibition of LOXL2 by genetic, chemical and antibody means leads to a significant decrease in the formation of distant metastases in both immunocompetent and immunocompromised orthotopic models of breast cancer without reducing primary tumor growth, suggesting that LOXL2 plays an important role in breast cancer metastasis.

Inhibition of LOXL2 in a transgenic model reduces lung metastases

Orthotopic models involving relatively homogeneous cell lines have their limitations. Therefore, we chose to further assess the role of LOXL2 in breast cancer metastasis using the well-established MMTV-PyMT transgenic model of ER− breast tumorigenesis (20, 27). Female MMTV-PyMT mice develop dysplastic lesions in the mammary epithelium around 3 weeks of age which progress to palpable mammary adenocarcinomas by 5 to 6 weeks of age and lung metastases with high penetrance by 8 to 9 weeks of age (20). Mice were given biweekly injections of D-penicillamine from 4 weeks of age (i.e., prior to initial tumor formation) for 4 weeks, or were left untreated. No significant difference in the rate of primary tumor growth was observed (data not shown). Mice were sacrificed around 10 weeks of age and lungs analyzed for metastases. Mice treated with D-penicillamine displayed significantly fewer lung metastases than control mice (P = 0.007; Fig. 2D, right panel). No differences in proliferation or apoptosis were observed in tumors or lungs of mice (Supplementary Fig. 4D). Importantly, initiating treatment in mice later than 5 weeks of age had no effect on metastatic burden (data not shown), suggesting that LOXL2 is required for the early stages of metastasis.

LOXL2 increases in vitro invasion

As invasion is the first step in metastasis, we tested the role of LOXL2 in invasion of 4T1 and MDA-MB-231 cells. Genetic knockdown of LOXL2 resulted in a significant decrease in invasion through collagen (P = 0.009 and P = 0.002 for 4T1 and MDA-MB-231 cells, respectively; Fig. 3A). Similar results were obtained when cells were subjected to transwell invasion assays through Matrigel (P = 0.001 and P = 0.014 for 4T1 and MDA-MB-231 cells, respectively; Fig. 3B). These findings suggest that LOXL2 is required for the invasive capabilities of these breast cancer cell lines.

Knockdown of LOXL2 decreases TIMP1

LOX enzymes modify the ECM, which can affect the expression and activity of other matrix-remodeling enzymes, enhancing tumor-cell invasion (18, 28). A recent study revealed a positive association between the expression of LOXL2, TIMP1 and matrix metalloproteinase-9 (MMP9) in human colorectal cancer, all were upregulated in CRC samples relative to normal colon tissue (29). We noted reduced secreted TIMP1 protein levels in 4T1 and MDA-MB-231 shLOXL2 cells (Fig. 4A), suggesting that LOXL2 regulates TIMP1 protein
Figure 4. LOXL2 regulates TIMP1. A, Western blot analysis of LOXL2 protein expression and TIMP1 in concentrated CM from 4T1/MDA-MB-231 cells expressing control or LOXL2 shRNA constructs, or transfected with siLOXL2 (compared with mock-transfected control). B, immunofluorescent images of tumor sections from mice bearing 4T1/MDA-MB-231 control or shLOXL2 tumors stained with TIMP1 (green) and 4′,6-diamidino-2-phenylindole (DAPI; blue). Scale bar, 100 μm. C, quantification of MDA-MB-231 control or siLOXL2 breast cancer cells +/- recombinant human TIMP1 invading through matrigel towards a chemoattractant. *P < 0.05. D, invasive branching structures formed by MDA-MB-231 control or siLOXL2 cells grown in 3D Matrigel, treated +/- recombinant human TIMP1. Scale bar, top; 500 μm, bottom; 200 μm.
expression in breast cancer cells. Furthermore, immunofluorescent staining of 4T1/MDA-MB-231 control and shLOXL2 tumors for TIMP1 showed that knockdown of LOXL2 resulted in decreased expression of TIMP1 (Fig. 4B), confirming our in vitro findings.

**Recombinant TIMP1 restores invasive ability of LOXL2 knockdown cells**

We tested whether TIMP1 could compensate for knockdown of LOXL2 in invasion. Recombinant TIMP1 protein was added to both control and LOXL2 knockdown cells, and cell invasion quantified. Addition of exogenous TIMP1 had no effect on the invasion of control cells. The LOXL2 knockdown cells exhibited a significantly decreased level of invasion as previously observed ($P = 0.023$; Fig. 4C). Importantly, TIMP1 was able to significantly restore the invasive capability of LOXL2 knockdown cells to the same level as control cells ($P = 0.032$; Fig. 4C), confirming a role in mediating invasion downstream of LOXL2.

MDA-MB-231 cells form invasive branching structures when grown in 3D matrix (21). We noted that LOXL2 knockdown cells formed round structures with fewer protrusions compared with control cells. Addition of exogenous TIMP1 protein to LOXL2 knockdown cells restored the ability of these cells to form protrusions in 3D Matrigel cultures (Fig. 4D). Similar results were observed when cells were grown in 3D collagen cultures (Supplementary Fig. 5A). These results confirm TIMP1 as a downstream mediator of LOXL2-driven invasion.

**Knockdown of LOXL2 decreases MMP9**

Although TIMP1 targets and inhibits the matrix metalloproteinase MMP9, it has been proposed that MMPs and TIMPs are coregulated and concurrently have been found to be upregulated in many tumor samples relative to normal tissue (30, 31). To assess the activity of MMP9 in control and shLOXL2 4T1/MDA-MB-231 cells, gelatin zymography was performed. Knockdown of LOXL2 in 4T1/MDA-MB-231 cells resulted in decreased MMP9 activity (Supplementary Fig. 5B), suggesting that LOXL2 also regulates the activity of MMP9. Furthermore, immunofluorescent staining of tumors for MMP9 showed that knockdown of LOXL2 resulted in decreased expression of MMP9 (Supplementary Fig. 5C), confirming our in vitro findings.

**High LOXL2 expression and activity during mammary gland involution**

Deregulation of normal signaling processes during morphogenesis can lead to tumorigenesis. Many cellular processes that control normal mammary gland development, such as tissue invasion, are characteristics of cancer progression. To gain further insight into the mechanism of action of LOXL2 in breast cancer progression, we analyzed LOXL2 expression during normal mammary gland development.

Samples were prepared from mammary glands harvested from FVB mice at different stages of mammary gland development. LOXL2 mRNA was expressed throughout development with highest expression during late pregnancy (Fig. 5A). The 150-kDa LOXL2 protein was expressed at all stages of mammary gland development (Supplementary Fig. 6A); however, highest levels of the 60-kDa LOXL2 protein were exhibited during lactation and involution (Fig. 5B). As LOXL2 is a matrix-modifying enzyme, these results suggest that LOXL2 plays a role in the remodeling of the mammary gland that occurs during involution.

Expression of the other LOX family members during mammary gland development was also analyzed. No change in expression of LOXL1, LOXL3, or LOXL4 was observed (data not shown). In contrast, LOX seemed to be most highly expressed during pregnancy and lactation (Supplementary Fig. 6A).

**TIMP1 is associated with LOXL2 during involution**

TIMPs and MMPs have been found to play roles in matrix remodeling during mammary gland development (32, 33). Therefore, we investigated the expression of TIMP1 during the various stages of mammary gland development. Expression of TIMP1 could only be detected during involution (Fig. 5B), when LOXL2 activity was highest (Fig. 5C). Active MMP9 was mostly associated with LOXL2, however, not as tightly as TIMP1 (Supplementary Fig. 6A).

We analyzed the expression of MMP2 and MMP14, two additional matrix-modifying enzymes found to be upregulated in invasive breast cancer (34). Although their expression was varied throughout mammary gland development (Supplementary Fig. 6A), they were not associated with LOXL2 activity, consistent with analysis of their expression in our control and shLOXL2 cell lines (data not shown). Therefore, TIMP1 seems to be specifically associated with LOXL2 expression and activity. It is likely that LOXL2 plays a role in modifying the mammary gland during involution not only through its action as a collagen cross-linker, but also through regulation of TIMP1.

**LOXL2 is expressed in basal epithelial and stromal cells**

To assess the mammary cell types expressing LOXL2, sections from different stages of mammary gland development were immunostained for LOXL2. Consistent with Western blotting results, LOXL2 protein was expressed at all stages of development (Supplementary Fig. 6B). LOXL2 staining appeared cytoplasmic in the basal epithelial cells, surrounding the luminal ductal epithelial cells (Fig. 6A). LOXL2 expression was also high in the stromal cells of the mammary gland (Supplementary Fig. 6B).

**LOXL2 is expressed in the basal/myoepithelial cell lineage**

Understanding the relationship between normal epithelial cell types and different disease states is required to provide insight into the specific cell types predisposed to carcinogenesis. Therefore, we analyzed the expression of LOXL2 in the 3 main cell lineages in normal mammary epithelium: the basal/myoepithelial, luminal ER+, and luminal ER− epithelial cell populations (25, 35). Primary mouse mammary epithelial cells were sorted into CD24+/Low/Sca-1− (basal/myoepithelial), CD24+/High/Sca-1− (ER−), and CD24+/High/Sca-1+ (ER+) populations. The 150-kDa LOXL2 protein was expressed at all stages of mammary gland development (Supplementary Fig. 6A); however, highest levels of the 60-kDa LOXL2 protein were exhibited during lactation and involution (Fig. 5B). As LOXL2 is a matrix-modifying enzyme, these results suggest that LOXL2 plays a role in the remodeling of the mammary gland that occurs during involution.

Expression of the other LOX family members during mammary gland development was also analyzed. No change in expression of LOXL1, LOXL3, or LOXL4 was observed (data not shown). In contrast, LOX seemed to be most highly expressed during pregnancy and lactation (Supplementary Fig. 6A).
populations (Supplementary Fig. 6C), and relative LOXL2 expression levels determined. Consistent with LOXL2 immunostaining, LOXL2 was highly expressed in the basal/myoepithelial cell population, compared with the luminal epithelial populations which exhibited very low levels of LOXL2 (Fig. 6C). The isolation of the basal/myoepithelial population was confirmed by analysis of the expression of 2 basal cell markers, Keratin-14 (K14) and p63 (Fig. 6B and Supplementary Fig. 6D).

To further confirm expression of LOXL2 in basal epithelial cells, mouse mammary gland sections were costained for LOXL2 and K14. Many basal cells (K14+) were also found to express LOXL2 (Fig. 6C). Finally, we analyzed our primary tumors and found that 4T1 shLOXL2 tumors exhibited reduced expression of the basal markers K14 and p63 (Fig. 6D and Supplementary Fig. 6D), confirming that high LOXL2 expression is associated with maintaining a more aggressive phenotype.

**Discussion**

More than 40,000 women die from metastatic breast cancer in the United States each year (36). Once metastases are detected, median survival is only 20 to 24 months (37). Thus, it is imperative that novel therapeutic strategies are developed and adopted for the treatment of patients with highly aggressive breast cancer.
Here, we show that high LOXL2 expression is correlated with decreased overall and metastasis-free survival in a subset of patients with aggressive breast cancer (ER− tumors). Therefore, LOXL2 expression may have prognostic value in determining which patients are most likely to develop metastatic disease. Furthermore, we analyzed the in vivo role of LOXL2 using orthotopic and transgenic mouse models of breast cancer, and showed that the size and number of distant metastases formed was significantly reduced. These results suggest that LOXL2 inhibitors should be considered in the development of new therapies for the treatment of metastatic breast cancer.

Despite its critical role in enabling metastasis, LOXL2 was found not to be essential for cell proliferation and primary tumor growth. In fact, growth was not significantly different for all treatments, save one exception: 4T1shLOXL2 tumors were found to consistently have a faster growth rate than control tumors, which could not be attributed to changes in

Figure 6. LOXL2 is expressed in stromal and basal epithelial cells. A, mammary gland sections from 8-week-old virgin and 2-day involution FVB mice stained with LOXL2 antibody and counterstained with hematoxylin. Arrows indicate cells expressing LOXL2. Scale bar, 50 μm. B, qRT-PCR analysis of LOXL2 and K14 mRNA expression in sorted mammary epithelial cell populations (basal/myoepithelial = CD24−/Sca-1−; luminal ER+ = CD24hi/Sca-1−; luminal ER− = CD24hi/Sca-1−). *** P < 0.001. C, mammary gland sections from 18-day pregnant (18 dP) and 8-day lactating (8 dL) FVB mice stained with LOXL2 (green) and K14 (red) antibodies and counterstained with DAPI (blue). Arrows indicate colocalisation of LOXL2 and K14 staining. Scale bar, 30 μm. D, 4T1 tumor sections stained with K14 antibody and counterstained with hematoxylin. Scale bar, 200 μm.
proliferation or apoptosis. As this effect was not observed when mice bearing 4T1 tumors were treated with a chemical and antibody inhibitor, nor in mice bearing MDA-MB-231shLOXL2 tumors compared with controls, we propose this could be due to increased LOX expression we observed in these cells only, as LOX has previously been shown to play a role in primary tumor growth in a breast cancer model (38).

We have previously shown that LOX is essential for breast cancer metastasis through effects on tumor-cell invasion and metastatic colonization (24, 39). Inhibition of LOX prevents CD11b+ cell recruitment required for premetastatic niche formation and reduces lung foci formation in tail vein metastasis assays (21, 24). However, unlike LOX, LOXL2 inhibition did not affect CD11b cell recruitment to the lungs or the number of lung foci formed (data not shown), suggesting that LOXL2 is not required for the initial formation of metastases. This is supported by the MMTV-PyMT model in which we noted that later inhibition of LOXL2, at a stage in which tumor cells had already disseminated, did not reduce the number of metastases. However, the size of metastases and lung foci were reduced with LOXL2 inhibition in our models, despite unaltered proliferation and apoptosis, suggesting some LOXL2 dependency for metastatic growth, although the mechanisms are subject to further investigation.

In this study, we found that LOX expression levels were not changed in response to LOXL2 inhibition (except increased in 4T1shLOXL2 cells, see above). However, invasion and metastasis were still suppressed in vitro and in vivo, suggesting that these enzymes cannot compensate for each other. Altered expression of the other LOX family members has been observed in various tumor types compared with normal tissue (3), however, we found no change in the expression of LOXL1, LOXL3, or LOXL4 in response to LOXL2 inhibition, suggesting they are not involved in LOXL2-mediated invasion and metastasis in our models.

A relevant article on LOXL2 was published while our manuscript was under revision. Barry-Hamilton and colleagues (40) showed that inhibition of LOXL2 using a monoclonal antibody significantly reduced bone metastases from intracardiac injection of MDA-MB-231, as we observed in our spontaneous 4T1 model. In contrast, the authors observed a significant reduction in primary tumor growth, which we did not observe in all three models we tested in response to genetic, chemical or antibody inhibition of LOXL2. However, this difference may be explained by different specificities of their LOXL2-targeting antibody.

We carried out in vitro assays to determine how LOXL2 drives the early stages of metastasis. We found that knockdown of LOXL2 decreased invasion and branching morphogenesis in 3D cultures. These findings support a role for LOXL2 in the early stages of metastasis, and support previous reports suggesting a role for LOXL2 in invasion (8–11). To understand the mechanism by which LOXL2 increases invasion of tumor cells, we studied other enzymes involved in remodeling of the ECM. We observed decreased TIMP1 and MMP9 expression in vitro and in vivo in response to LOXL2 knockdown. TIMP1 was found to functionally compensate for LOXL2 knockdown in invasion and branching assays. Cross-linking of collagens is known to activate enzymes involved in matrix remodeling, such as MMPs (18, 24). We propose that this is the mechanism by which LOXL2 increases TIMP1 and MMP9, thereby increasing degradation/remodeling of the ECM and enabling subsequent metastatic dissemination.

We examined normal mammary gland development to gain further insight into the mechanism of action of LOXL2. Breakdown of the basement membrane and ECM remodeling are prominent features of mammary gland involution (41). Furthermore, processes that are known to promote tumorigenesis, play major roles in modifying the mammary microenvironment during involution (42, 43). LOXL2 was expressed during all stages of mammary gland development but was most active in the involuting mammary gland, when extensive ECM remodeling is taking place. Importantly, we also observed high TIMP1 and MMP9 during involution, providing further evidence that LOXL2 activity regulates the expression of these proteins involved in matrix remodeling.

Recently, a mouse mammary gland involution mRNA signature was found to predict breast cancers with high metastatic activity in the NKI 295 microarray data set we used for our initial prognostic study (44). Not only did Stein and colleagues (44) link genes associated with involution to breast cancer metastasis, but also genes associated with hypoxia and copper ion homeostasis, two important regulators of LOXL2 (45, 46). Furthermore, we also show that LOXL2 is expressed in mammary stroma and basal epithelial cells surrounding the mammary ducts. Our analysis of the three main cell lineages in the mammary gland confirmed that LOXL2 is expressed in the basal/myoepithelial compartment. Cells in this population express many genes common to basal-like tumors, the most aggressive form of breast cancer (47, 48). Finally, we found reducing the expression of LOXL2 in basal tumors led to a decrease in the expression of the basal markers K14 and p63. Taken together, these data support our observations that LOXL2 expression is elevated in the involuting mammary gland, in aggressive breast cancer cell lines, in patients with poor prognosis, and facilitates the progression of breast cancer.

In conclusion, our data show that LOXL2 is a potent mediator of breast cancer metastasis through effects on tumor-cell invasion and regulation of matrix-remodeling proteins. These same proteins are associated with LOXL2 activity in the involuting mammary gland. We show that LOXL2 correlates with poor prognosis in breast cancer patients, and provide preclinical evidence that targeting LOXL2 is effective against breast cancer metastases. These findings clearly show that LOXL2 is an excellent therapeutic target against metastatic breast cancer.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

The authors thank Andreas Hadjiprocopis for assistance with statistics, Kay Savage for histopathology, Fredrik Walberg for assistance with flow cytometry, Samra Turalic and Grazia Saturno for STR analysis, and Clare Isacke and Matt Smalley plus lab members at ICR for assistance.
Reference Information

The work received financial support from the following: The Institute of Cancer Research (H.E. Barker, J.T. Erler), the Breast Cancer Campaign (ref 2008NovPhD17, JC), Cancer Research UK (ref C107/A10433, T.R. Cox, G. Lang, D. Bird, J.T. Erler). All in vivo experiments were approved by the Home Office and conducted following UKCCCR Guidelines for the welfare and use of animals in cancer research.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received August 6, 2010; revised November 16, 2010; accepted December 28, 2010; published OnlineFirst January 13, 2011.


# LOXL2-Mediated Matrix Remodeling in Metastasis and Mammary Gland Involution

Holly E. Barker, Joan Chang, Thomas R. Cox, et al.


<table>
<thead>
<tr>
<th>Updated version</th>
<th>Access the most recent version of this article at: doi:10.1158/0008-5472.CAN-10-2868</th>
</tr>
</thead>
<tbody>
<tr>
<td>Supplementary Material</td>
<td>Access the most recent supplemental material at: <a href="http://cancerres.aacrjournals.org/content/suppl/2011/01/12/0008-5472.CAN-10-2868.DC1">http://cancerres.aacrjournals.org/content/suppl/2011/01/12/0008-5472.CAN-10-2868.DC1</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cited articles</th>
<th>This article cites 48 articles, 12 of which you can access for free at: <a href="http://cancerres.aacrjournals.org/content/71/5/1561.full#ref-list-1">http://cancerres.aacrjournals.org/content/71/5/1561.full#ref-list-1</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Citing articles</td>
<td>This article has been cited by 18 HighWire-hosted articles. Access the articles at: <a href="http://cancerres.aacrjournals.org/content/71/5/1561.full#related-urls">http://cancerres.aacrjournals.org/content/71/5/1561.full#related-urls</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>E-mail alerts</th>
<th>Sign up to receive free email-alerts related to this article or journal.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reprints and Subscriptions</td>
<td>To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at <a href="mailto:pubs@aacr.org">pubs@aacr.org</a>.</td>
</tr>
<tr>
<td>Permissions</td>
<td>To request permission to re-use all or part of this article, use this link: <a href="http://cancerres.aacrjournals.org/content/71/5/1561">http://cancerres.aacrjournals.org/content/71/5/1561</a>. Click on &quot;Request Permissions&quot; which will take you to the Copyright Clearance Center's (CCC) Rightslink site.</td>
</tr>
</tbody>
</table>